Metastatic colorectal cancer: mechanisms and emerging therapeutics.
Trends Pharmacol Sci
; 44(4): 222-236, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-36828759
ABSTRACT
Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with or without adjuvant chemotherapy, mCRC cannot be eradicated due to a large burden of disseminated cancer cells comprising therapy-resistant metastasis-competent cells. To address this gap, recent studies have focused on further elucidating the molecular mechanisms underlying colorectal metastasis and recognizing the limitations of available therapeutic interventions. In this review, we discuss newfound factors that regulate CRC cell dissemination and colonization of distant organs, such as genetic mutations, identification of metastasis-initiating cells (MICs), epithelial-mesenchymal transition (EMT), and the tumor microenvironment (TME). We also review current treatments for mCRC, therapeutic regimens undergoing clinical trials, and trending preclinical studies being investigated to target treatment-resistant mCRC.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Colorrectales
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Trends Pharmacol Sci
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos